Rankings
▼
Calendar
ALKS Q1 2020 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena
ALKS
Alkermes plc
$5B
Q1 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$246M
+10.4% YoY
Gross Profit
$199M
80.8% margin
Operating Income
-$37M
-15.2% margin
Net Income
-$39M
-15.7% margin
EPS (Diluted)
$-0.24
QoQ Revenue Growth
-40.3%
Cash Flow
Operating Cash Flow
-$40M
Free Cash Flow
-$60M
Stock-Based Comp.
$20M
Balance Sheet
Total Assets
$1.8B
Total Liabilities
$763M
Stockholders' Equity
$1.1B
Cash & Equivalents
$176M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$246M
$223M
+10.4%
Gross Profit
$199M
$178M
+12.0%
Operating Income
-$37M
-$76M
+50.8%
Net Income
-$39M
-$96M
+59.9%
Revenue Segments
Product
$130M
50%
Vivitrol
$79M
30%
Aristada Or Aristada Initio
$51M
20%
← FY 2020
All Quarters
Q2 2020 →